Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

HLA screening for ABV hypersensitivity reaction

July 28, 2008

Analysis of:F.D.A. Urges Genetic Test Before Giving AIDS Drug | www.nytimes.com

After the extensive studies published (Mallal et al), it becomes mandatory to perform a genetic HLA screening before starting abacavir-containing antiretroviral associations. Problems are recognizable in these points: - laboratories are not capable to front an exaggerated request of HLA typing; - ad-hoc funding have not been allocated previously - medical-legal problems are expected in the event of prescription of ABC-containing regimen without a preliminary HLA screening, should a severe reaction occurs (average occurrence: 8% of patients)

To consider the possible role of the new NNRTI etravirine in the treatment of HIV infection

February 27, 2008

Analysis of:Promising phase I/II data in HIV with once-daily NNRTI from Idenix | www.pipelinereview.com

Etravirine is a novel and very promising NNRTI since it has not cross-resistance with the existing NNRTIs (efavirenz and nevirapine), and also encompasses excellent efficacy, convenience, and a good tolerability.

Page : 11 to 2 of 2

Subscribe to Updates

By RSS